BiotechTubeBiotechTube
Home/ATXA Therapeutics/Jonathan Langley
JL

Jonathan Langley

Appointed Role (2020)

ATXA Therapeutics

Therapeutic Areas

CardiopulmonaryPulmonary Arterial HypertensionHeart FailureInterstitial Lung DiseaseOncology

ATXA Therapeutics Pipeline

DrugIndicationPhase
NTP42Pulmonary Arterial Hypertension (PAH)Phase 1

Leadership Team at ATXA Therapeutics

PT
Professor Therese Kinsella
Founder & CEO
EM
Eamon Mulvaney
Author/Communications Lead (inferred)
View full ATXA Therapeutics profile